New Zealand markets close in 3 hours 24 minutes

Histogen Inc. (HSTO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.3200-0.0010 (-0.31%)
At close: 03:04PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.3210
Bid0.0000 x 1200
Ask0.0000 x 1000
Day's range0.3200 - 0.3200
52-week range0.3000 - 1.6200
Avg. volume270,020
Market cap1.367M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-2.8100
Earnings date07 Mar 2024 - 11 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Histogen Announces Adjournment of Special Meeting of Stockholders

    Meeting Adjourned to December 14, 2023 at 8:00 a.m. PT Histogen Special Meeting QR Code Histogen Special Meeting QR Code SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on Octobe

  • GlobeNewswire

    Histogen Announces Board Approval of Complete Liquidation and Dissolution

    SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connecti

  • GlobeNewswire

    Histogen to Explore Strategic Alternatives

    SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs